Treatment of the cell line with ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist widely used as analgesic for cancer pain treatment, decreases the p300-recruitment on PVT1 promoter, thus inhibiting the lncRNA repressing activity on CDKN1C expression [279]. This evidence concerns the gene CDKN1C and cancer.